Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario

American Journal of Hypertension
Enayet K ChowdhuryDanny Liew

Abstract

Renal denervation (RDN) is effective at reducing blood pressure (BP) among patients with treatment-resistant hypertension (TRH). However, recent findings regarding the effectiveness of RDN for BP reduction compared with standard treatment of care (SoC) has initiated a rigorous debate about its role in TRH management. In this study, we sought to determine the thresholds for cardiovascular risk and costs of RDN which would make RDN cost-effective. A Markov model was constructed to simulate cardiovascular events over a lifetime among TRH subjects aged 60 years at baseline, and without prior cardiovascular disease. The effect on lowering BP was based on results observed in clinical trials of RDN undertaken to date, and the expected subsequent change to cardiovascular risk was drawn from a published meta-regression. Cost and utility data were drawn from published sources. Incremental cost-effectiveness ratios (ICER) in terms of Australian dollars (AUD) per life year and per quality-adjusted life year (QALY) gained were estimated to assess RDN cost-effectiveness relative to SoC from the Australian health care perspective, assuming a willingness-to-pay threshold of AUD 50,000. Over a lifetime horizon, the model predicted that at the c...Continue Reading

References

Sep 8, 2000·PharmacoEconomics·A H Briggs
Jun 5, 2002·The Journal of Clinical Hypertension·J D SteinH D Stein
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
Apr 2, 2008·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Anthony H HarrisEmily Walkom
May 14, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Shiori Amemiya, Hidemasa Takao
Apr 13, 2011·BMJ : British Medical Journal·Stavros Petrou, Alastair Gray
Dec 27, 2011·Heart·Robert H Fagard
Mar 2, 2012·Circulation·Stacie L DaughertyP Michael Ho
Sep 18, 2012·Journal of the American College of Cardiology·Benjamin P GeislerJan B Pietzsch
Nov 22, 2012·BMJ : British Medical Journal·Aung MyatBryan Williams
Feb 5, 2013·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·B D Schoub
Jun 19, 2013·Nature Reviews. Cardiology·Michael BöhmChristian Ukena
Sep 21, 2013·American Journal of Hypertension·Steven M Smith, Jonathan D Campbell
Apr 1, 2014·The New England Journal of Medicine·Deepak L BhattUNKNOWN SYMPLICITY HTN-3 Investigators
Aug 5, 2014·Applied Health Economics and Health Policy·Daniel GladwellRon Akehurst
Nov 18, 2014·European Heart Journal·David E KandzariGeorge L Bakris
Aug 18, 2016·JAMA : the Journal of the American Medical Association·Dhruv S KaziKirsten Bibbins-Domingo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.